Biode 6和Bio-Rad正在开发乳腺癌突变的敏感测试,以指导治疗和改善存活率。 Biodesix and Bio-Rad are developing a sensitive test for breast cancer mutations to guide treatment and improve survival.

Biode 6扩大了与Bio-Rad的伙伴关系,以开发和验证利用滴子数字PCR技术在循环肿瘤DNA过程中对ESR1突变进行高度敏感的测试。 Biodesix has expanded its partnership with Bio-Rad to develop and validate a highly sensitive test for ESR1 mutations in circulating tumor DNA using Droplet Digital PCR technology. ddPLEX ESR1实验针对先进的乳腺癌病人,支持与改善生存有关的口服SERD疗法的治疗。 The ddPLEX ESR1 assay, aimed at advanced breast cancer patients, supports treatment with oral SERD therapies linked to improved survival. Biode6将验证测试,管理监管呈件,并通过其CLIA-CAP实验室提供,供研究和临床使用,并计划寻求CMS补偿。 Biodesix will validate the test, manage regulatory submissions, and offer it through its CLIA-CAP lab for research and clinical use, with plans to seek CMS reimbursement. 合作以先前的肿瘤学工作为基础,将在11月的非洲管理计划会议上详细介绍。 The collaboration builds on prior oncology work and will be detailed at the AMP conference in November.